Natco Pharma aims to diversify product portfolio in domestic market

21 Sep 2020 Evaluate

Natco Pharma is planning to diversify its product portfolio in the domestic market as it aims to make up for a drop in business of some of its prominent product categories. Its oncology segment suffered in the last financial year due to pricing controls from the government, and its Hepatitis-C business continued to decline due to reduction in market size. The company is planning for new product launches in the non-oncology segment to mitigate the impact of the Hepatitis-C market decline.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

817.00 -14.75 (-1.77%)
27-Jan-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1636.05
Dr. Reddys Lab 1240.00
Cipla 1313.20
Zydus Lifesciences 895.85
Lupin 2147.60
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×